Nu Skin Enterprises, Inc. (NYSE:NUS) – Research analysts at DA Davidson issued their Q3 2018 earnings estimates for Nu Skin Enterprises in a research note issued to investors on Tuesday, October 9th. DA Davidson analyst L. Weiser forecasts that the company will earn $0.96 per share for the quarter. DA Davidson currently has a “Buy” rating and a $92.00 target price on the stock. DA Davidson also issued estimates for Nu Skin Enterprises’ Q4 2018 earnings at $1.08 EPS, FY2018 earnings at $3.58 EPS, Q1 2019 earnings at $0.78 EPS, Q2 2019 earnings at $1.11 EPS, Q3 2019 earnings at $1.04 EPS, Q4 2019 earnings at $1.22 EPS, FY2019 earnings at $4.15 EPS and FY2020 earnings at $4.70 EPS.
Nu Skin Enterprises (NYSE:NUS) last issued its quarterly earnings data on Thursday, August 2nd. The company reported $1.08 earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of $0.90 by $0.18. The company had revenue of $704.19 million for the quarter, compared to analyst estimates of $642.16 million. Nu Skin Enterprises had a net margin of 5.74% and a return on equity of 25.67%. The company’s revenue was up 28.0% on a year-over-year basis. During the same period in the prior year, the firm earned $0.77 earnings per share.
A number of other equities analysts have also commented on NUS. Zacks Investment Research raised shares of Nu Skin Enterprises from a “sell” rating to a “hold” rating and set a $95.00 price target on the stock in a research report on Monday, August 6th. Jefferies Financial Group reaffirmed a “buy” rating and set a $98.00 price target on shares of Nu Skin Enterprises in a research report on Tuesday, September 4th. Finally, Stifel Nicolaus raised shares of Nu Skin Enterprises from a “sell” rating to a “hold” rating and raised their price target for the stock from $57.00 to $70.00 in a research report on Thursday, August 2nd. They noted that the move was a valuation call. Three equities research analysts have rated the stock with a hold rating and five have issued a buy rating to the company’s stock. Nu Skin Enterprises has a consensus rating of “Buy” and a consensus target price of $86.29.
Shares of NUS opened at $68.66 on Thursday. The stock has a market capitalization of $4.58 billion, a PE ratio of 20.94, a P/E/G ratio of 2.35 and a beta of 1.06. Nu Skin Enterprises has a fifty-two week low of $59.31 and a fifty-two week high of $88.68. The company has a debt-to-equity ratio of 0.46, a quick ratio of 1.19 and a current ratio of 1.82.
In related news, Director Edwina D. Woodbury sold 5,000 shares of the firm’s stock in a transaction dated Monday, August 6th. The shares were sold at an average price of $85.02, for a total transaction of $425,100.00. Following the transaction, the director now directly owns 11,860 shares of the company’s stock, valued at $1,008,337.20. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink. Also, General Counsel D Matthew Dorny sold 2,500 shares of the stock in a transaction dated Monday, October 1st. The stock was sold at an average price of $82.18, for a total transaction of $205,450.00. Following the sale, the general counsel now owns 33,871 shares in the company, valued at $2,783,518.78. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 42,850 shares of company stock worth $3,523,563. 3.00% of the stock is owned by insiders.
A number of institutional investors have recently made changes to their positions in NUS. BlackRock Inc. grew its stake in Nu Skin Enterprises by 11.5% during the second quarter. BlackRock Inc. now owns 6,143,407 shares of the company’s stock worth $480,352,000 after buying an additional 635,246 shares in the last quarter. Millennium Management LLC grew its stake in Nu Skin Enterprises by 937.5% during the first quarter. Millennium Management LLC now owns 422,098 shares of the company’s stock worth $31,113,000 after buying an additional 381,414 shares in the last quarter. Renaissance Technologies LLC grew its stake in Nu Skin Enterprises by 51.1% during the second quarter. Renaissance Technologies LLC now owns 814,000 shares of the company’s stock worth $63,647,000 after buying an additional 275,200 shares in the last quarter. Acadian Asset Management LLC grew its stake in Nu Skin Enterprises by 112.2% during the second quarter. Acadian Asset Management LLC now owns 368,804 shares of the company’s stock worth $28,834,000 after buying an additional 194,990 shares in the last quarter. Finally, OppenheimerFunds Inc. grew its stake in Nu Skin Enterprises by 1,497.3% during the first quarter. OppenheimerFunds Inc. now owns 148,041 shares of the company’s stock worth $10,912,000 after buying an additional 138,773 shares in the last quarter. Hedge funds and other institutional investors own 76.00% of the company’s stock.
Nu Skin Enterprises Company Profile
Nu Skin Enterprises, Inc develops and distributes anti-aging personal care products and nutritional supplements under the Nu Skin and Pharmanex category brands worldwide. It provides skin care systems and targeted treatment products, including ageLOC Me customized skin care systems, ageLOC Spa systems, and ageLOC LumiSpa skin treatment and cleansing devices; and Epoch products, as well as a range of other cosmetic, personal care, and hair care products.
Read More: What Is An Exchange-Traded Fund (ETF)?
Receive News & Ratings for Nu Skin Enterprises Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nu Skin Enterprises and related companies with MarketBeat.com's FREE daily email newsletter.